The company closed its plan on March 26, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
176,200 KRW | -0.62% | -2.06% | -12.56% |
May. 24 | Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe | CI |
May. 10 | Celltrion's Q1 Attributable Profit Slumps 86% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.56% | 26.22B | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+37.43% | 38.82B | |
+14.75% | 26.86B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- A068270 Stock
- News Celltrion, Inc.
- Celltrion, Inc.'s Equity Buyback announced on March 5, 2024, has closed with 425,895 shares, representing 0.21% for KRW 78,072.21 million.